Collaborating for Cures
Leveraging Global Public-Private Partnerships to Accelerate Biopharmaceuticals Development

First Joint IMI & C-Path Forum on the Value of PPPs
Thursday 7 March 2013 – Brussels, Belgium
The Sheraton Hotel, Brussels Airport

9:00-10:00   Registration and refreshments

10:00-10:30   Welcome and introduction
Michel Goldman, Executive Director, IMI
Martha Brumfield, President and CEO, C-Path

10:30-12:30   Innovative solutions to shared challenges
Roundtable discussion – what challenges do PPPs face in areas such as knowledge management, sustainability, data sharing protection, intellectual property, ensuring industry involvement, addressing patients’ concerns, and evaluating the added value of PPPs? What solutions are in place and what challenges remain?
Chair: Orla Smith, Managing Editor, Science Translational Medicine
Panellists:
- Maria Freire, President, Foundation for the National Institutes of Health (FNIH)
- Tania Bubela, University of Alberta
- Alastair Benbow, Chief Executive, The Age of the Brain
- Hans-Georg Eichler, Senior Medical Officer, EMA
- ShaAvhree Buckman-Garner, Director, Drug Evaluation & Translational Science, FDA
- Richard Bergström, Director General, EFPIA

12:30-13:30   Lunch

13:30-15:30   IMI and C-Path collaboration on Alzheimer’s disease
Session Chair: Dr Elisabetta Vaudano, IMI Principal Scientific Manager
Speakers: IMI’s PharmaCog project – Jill Richardson, GlaxoSmithKline
IMI’s EMIF project - Simon Lovestone, King’s College London
C-Path’s Coalition Against Major Diseases (CAMD) - Diane Stephenson, Executive Director

Panel discussion on the outcomes of the projects and their relevance in particular to regulators and patients
- Jill Richardson, GSK
- Simon Lovestone, King’s College London
- Diane Stephenson, CAMD

15:30-16:00  Tea / coffee break

16:00-17:30  IMI and C-Path collaboration on tuberculosis
Session Chair: Dr Elisabetta Vaudano, IMI Principal Scientific Manager
Speakers: IMI’s Predict-TB project – Justin Green, GSK & Gerry Davis, University of Liverpool
C-Path’s Critical Path to TB Drug Regimens (CPTR) project - Debra Hanna, Executive Director

Panel discussion on the outcomes of the projects and their relevance in particular to regulators and patients
- Justin Green, GlaxoSmithKline
- Gerry Davies, University of Liverpool
- Debra Hanna, CPTR
- Bron Kisler, Clinical Data Interchange Standards Consortium (CDISC)
- Ed Cox, FDA
- Joe Toerner, FDA
- Marco Cavaleri, EMA

17:30-17:50  Conclusions
Michel Goldman, Executive Director, IMI
Martha Brumfield, President and CEO, C-Path

17:50  End of the meeting